Intersys’ Risk Director Catherine Geyman was one of three authors of the ReMediES white paper Understanding Risk in Pharmaceutical Supply Chains.
The result of a four-year-long collaboration with University of Cambridge, AstraZeneca, GSK and other industry leaders, the paper looks at different aspects of risk management in the pharmaceutical supply chain.
The many areas covered include triggers for drug shortages and a risk-benefit analysis of clinical just-in-time manufacture.
The paper features three distinct methods to help our understanding of drug shortages. These are:
Catherine Geyman was involved in all areas of the project and led the disruption prediction analysis, using analytics that are integral to SCAIR®’s Regulatory Incident Monitor.